摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-n-butyl-4,6-dichloropyrimidine | 90086-01-4

中文名称
——
中文别名
——
英文名称
2-n-butyl-4,6-dichloropyrimidine
英文别名
2-butyl-4,6-dichloro-pyrimidine;2-Butyl-4,6-dichlorpyrimidin;2-Butyl-4,6-dichloropyrimidine
2-n-butyl-4,6-dichloropyrimidine化学式
CAS
90086-01-4
化学式
C8H10Cl2N2
mdl
——
分子量
205.087
InChiKey
JLCLIVLRRYIDGQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    262.2±20.0 °C(Predicted)
  • 密度:
    1.238±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    戊腈盐酸sodium ethanolate三氯氧磷 作用下, 以 乙醇 为溶剂, 反应 105.0h, 生成 2-n-butyl-4,6-dichloropyrimidine
    参考文献:
    名称:
    2-取代的6-羟基-[3H]-嘧啶-4-酮和4,6-二氯嘧啶的“绿色”合成:改进的策略和机理研究*
    摘要:
    一种改进的路线2-取代的6-羟基- [3 H ^ ] -嘧啶-4-酮4和2-取代的4,6-二氯嘧啶5报道。不使用剧毒反应物,就可以方便地在一锅合成中以1摩尔规模制备化合物4,平均收率可达80%。通常使用少量原料制备的4,6-二氯嘧啶5的平均收率为80%,最多可使用80 g起始原料。4氯化的机理是第一次进行计算研究。结果表明,磷酰氯的氯化反应以交替的磷酸化-氯化方式(途径1)进行,这比以两次磷酸化开始的顺序更可取。本文所述的研究的4,6-二氯嘧啶与二氯磷酸形成强络合物,但与盐酸形成弱络合物(在后处理期间生成)。后面这些配合物解释了在后处理过程中使用碳酸钠水溶液的必要性。为了防止在中间体或最终的二氯嘧啶和未反应的羟基嘧啶之间形成嘧啶鎓盐,可以用强酸(例如二氯磷酸)使后者失活,从而进行氯化反应,但阻止形成盐。
    DOI:
    10.1071/ch14073
点击查看最新优质反应信息

文献信息

  • Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
    申请人:Meguro Masaki
    公开号:US20050054732A1
    公开(公告)日:2005-03-10
    The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).
    本发明涉及预防或治疗阿尔茨海默病的药物或药物,或β淀粉样蛋白纤维形成抑制剂,其中包括通式(I)下的化合物或其药学上允许的盐作为活性成分;还涉及具有特定取代基的含氮杂环衍生物或其药学上允许的盐,其作为防治阿尔茨海默病的药物或β淀粉样蛋白纤维形成抑制剂具有价值:(其中,R1和R2是H或烷基;Z1和Z2是H,烷基,烷氧基,卤代烷基或卤素基;Z3是烷氧基,SH,烷硫基,NH2,单或双烷基氨基,OH或卤素基;Z4和Z5是H或卤素基;A是4,6-嘧啶-1,3-二基,1,3,5-三嗪-2,6-二基等)。
  • Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
    申请人:Meguro Masaki
    公开号:US20080182846A1
    公开(公告)日:2008-07-31
    The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).
    本发明涉及用于预防或治疗阿尔茨海默病的药物或疗法,或者用于抑制淀粉样蛋白纤维形成的药物,其中包括通式(I)所示的化合物或其药学上允许的盐作为活性成分;以及具有特定取代基的含氮杂环衍生物或其药学上允许的盐,它们对于预防或治疗阿尔茨海默病或作为淀粉样蛋白纤维形成抑制剂非常有价值。(其中,R1和R2为H或烷基;Z1和Z2为H、烷基、烷氧基、卤代烷基或卤素;Z3为烷氧基、SH、烷基硫醇、NH2、单烷基或二烷基氨基、OH或卤素;Z4和Z5为H或卤素;A为4,6-嘧啶-1,3-二基、1,3,5-三嗪-2,6-二基等)。
  • Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
    申请人:Meguro Masaki
    公开号:US20090286794A1
    公开(公告)日:2009-11-19
    The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).
    本发明涉及用于防治阿尔茨海默病的预防剂或治疗剂,或淀粉样蛋白纤维形成抑制剂,其包括以下通式(I)的化合物或其药理学许可盐作为活性成分;以及具有特定取代基的含氮杂芳基衍生物,或其药理学许可盐,它们作为防治阿尔茨海默病的预防剂或治疗剂,或淀粉样蛋白纤维形成抑制剂具有重要价值:(其中,R1和R2为H或烷基;Z1和Z2为H、烷基、烷氧基、卤代烷基或卤素;Z3为烷氧基、SH、烷硫基、NH2、单烷基或二烷基氨基、OH或卤素;Z4和Z5为H或卤素;A为4,6-嘧啶-1,3-二基、1,3,5-三嗪-2,6-二基等)。
  • PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS
    申请人:BTG INTERNATIONAL LIMITED
    公开号:EP1473289B1
    公开(公告)日:2009-08-05
  • US7589105B2
    申请人:——
    公开号:US7589105B2
    公开(公告)日:2009-09-15
查看更多